Our Pipeline

We are advancing a robust portfolio of locally and systemically administered oncolytic virus therapies across our Herpes Simplex Virus (HSV) and our Synthetic Virus Platform. This will enable us to pursue multiple indications with the potential to help transform outcomes for more cancer patients.